Notes to Consolidated Financial Statements
May 31, 2014
Unaudited
Note 1 Basis of Presentation
The accompanying unaudited interim consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X
of the United States Securities and Exchange Commission (“SEC”). Certain information or footnote disclosures normally
included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America
have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly,
they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results
of operations, or cash flows. It is our opinion, however, that the accompanying unaudited interim consolidated financial statements
include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial
position, operating results and cash flows for the periods presented.
In the quarter ending May 31, 2014, the
Company has elected to early adopt Accounting Standards Update No. 2014-10, Development Stage Entities (Topic 915): Elimination
of Certain Financial Reporting Requirements. The adoption of this ASU allows the Company to remove the inception to date information
and all references to development stage.
The accompanying unaudited interim consolidated
financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended November 30, 2013
as filed with the SEC, which contains the audited financial statements and notes thereto, together with Management’s Discussion
and Analysis, for the years ended November 30, 2013 and 2012. The financial information as of May 31, 2014 is derived from the
audited financial statements presented in our Annual Report on Form 10-K for the year ended November 30, 2013. The interim
results for the three and six months ended May 31, 2014 are not necessarily indicative of the results to be expected for the year
ending November 30, 2014 or for any future interim periods.
Reverse Stock Split
On August 6, 2013, the Company effected
a 1-for-5 reverse stock split of its commons stock (“Reverse Split”). As a result of the Reverse Split, every five
shares of the common stock of the Company were combined into one share of common stock. Immediately after the September 4, 2013
effective date, the Company had 18,056,007 shares of common stock issued and outstanding. All share and per share amounts have
been retroactively restated to reflect the Reverse Split. Effective at the same time as the Reverse Split, the authorized number
of shares of our common stock was proportionately decreased from 500,000,000 shares to 100,000,000 shares. The par value remained
the same.
Note 2 Going Concern
As reflected in the accompanying consolidated
financial statements, the Company had a net loss of $545,729 and net cash used in operations of $220,264 for the six months ended
May 31, 2014. Additionally, the Company had a working capital deficit of $2,037,388 and a stockholders’ deficit of $1,998,790
at May 31, 2014. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
The ability of the Company to continue
as a going concern is dependent on Management's plans, which include potential asset acquisitions, mergers or business combinations
with other entities, further implementation of its business plan and continuing to raise funds through debt and/or equity financings.
The Company will likely rely upon related party debt and/or equity financing in order to ensure the continuing existence of the
business.
The accompanying consolidated financial
statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded
assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
BioPower Operations Corporation and Subsidiaries
Notes to Consolidated Financial Statements
May 31, 2014
Unaudited
Note 3 Equipment
At May 31, 2014 and November 30, 2013,
equipment consists of the following:
|
|
2014
|
|
|
2013
|
|
|
Estimated Useful Life
|
Computer Equipment and Testing Equipment
|
|
$
|
48,126
|
|
|
$
|
43,402
|
|
|
5 years
|
Less: Accumulated depreciation
|
|
|
(20,721
|
)
|
|
|
(14,551
|
)
|
|
|
Equipment, net
|
|
$
|
27,405
|
|
|
$
|
28,821
|
|
|
|
Note 4. Notes Payable and Convertible
Debt
Notes payable consists of the following:
Notes payable to third parties at May 31,
2014 and November 30, 2013, in the amount of $70,000 due on demand at 4% and $18,000 due on demand at 8%. Accrued interest at May
31, 2014, and November 30, 2013 amounted to $1,887 and $6,149, respectively, which is included as a component of accounts payable
and accrued expenses. Interest expense on notes payable to third parties amounted to $381 and $3,655 for the three months ended
May 31, 2014 and 2013, respectively.
The following is a summary of the Company’s
convertible debt at May 31, 2014 and November 30, 2013:
|
|
|
|
|
Interest
|
|
|
|
|
|
Balance
|
|
|
Rate
|
|
|
Maturity
|
Balance - November 30, 2013
|
|
$
|
125,000
|
|
|
|
8
|
%
|
|
Jan. 22, 2015
|
Borrowings
|
|
|
125,000
|
|
|
|
8
|
%
|
|
Feb. 3, 2015
|
Balance - May 31, 2014
|
|
$
|
250,000
|
|
|
|
|
|
|
|
On December 3, 2013 a third party investor
advanced $125,000 due in 14 months from the date of the loan. Up to 50% of the original amount of the debt is convertible into
the Company’s commons shares at a price of $0.10 per share, which the investor can choose to convert prior to the maturity
date and before the redemption date. If the closing price per share of common stock exceeds $0.25 for any ten consecutive trading
days, the Company has the right to redeem the Notes by providing investor notice of redemption to redeem the note (“redemption
date”).
Accrued interest at May 31, 2014 and November
30, 2013 amounted to $24,289 and $1,263, respectively, which is included as a component of accounts payable and accrued expenses.
Interest expense on convertible debt with
third parties amounted to $5,729 and $252 for the three month period ending May 31, 2014 and May 31, 2013, respectively.
Note 5 .Related Party Transactions
Notes payable to related parties at May
31, 2014 and November 30, 2013 is $175.
Accrued interest at May 31, 2014 and November
30, 2013, amounted to $190 and is a component of accounts payable and accrued expenses – related parties. Interest expense
on notes payable to related parties amounted to $-0- and $400 for the three months ended May 31, 2014 and May 31, 2013, respectively.
The Company has separated accounts payable
and accrued expenses on the balance sheet to reflect amounts due to related parties primarily consisting of officer compensation,
health insurance, interest on notes and reimbursable expenses to officers for travel, meals and entertainment, vehicle and other
related business expenses.
BioPower Operations Corporation and Subsidiaries
Notes to Consolidated Financial Statements
May 31, 2014
Unaudited
Note 6. Stockholders’ Deficit
(A) Common Stock
The Company issued 250,000 shares during
the quarter ended May 31, 2014, pursuant to the terms of a consulting agreement. The Company has entered into a six month consulting
agreement with Caro Capital LLC to provide services for management consulting, business advisory, shareholder information and public
relations. The Company will pay the consulting firm up to $12,000 and provide 500,000 shares of restricted common stock, according
to the terms of the agreement. As of May 31, 2014, 250,000 shares valued at $27,400 were issued according to the terms of the agreement.
There are 30,531,180 shares and 30,281,180 shares issued and outstanding at May 31, 2014 and November 30, 2013, respectively.
(B) Restricted Stock
On June 21, 2013, the Company granted 1,500,000
shares of common stock to a consultant for services to be provided over a twelve month period, commencing June 1, 2013. The shares
will vest after one year of service; however the Company issued the shares in September 2013. The value of the shares is trued
up quarterly over the period. For the three months ended May 31, 2014, the company recognized a $37,500 decrease in expense, bringing
the total expense for these restricted shares to $120,000 and a reduction of $23,750 for the six months ended May 31, 2014. All
of the shares have vested as of May 31, 2014.
In addition, the Company will pay the consultant
a fee of $7,500 per month, cash flow permitting, over the same twelve month period. Accrued consulting fees at May 31, 2014 amounted
to $ 75,000 related to the cash portion of fees due, which is included as a component of accounts payable and accrued expenses.
Consulting fee expense amounted to $ 22,500 for the three months ended May 31, 2014.
On June 25, 2013, the
Company’s Chief Executive Officer and Director of Business Strategy were each granted 2,000,000 shares of common stock
in exchange for continuing to work without cash payment of their full salary and to convert accrued expenses and a note
payable (see Note 9). The shares will vest after one year of service and will not replace the Company’s obligation to
pay the required salary over the next year. The fair value of the common stock at the date of grant was $ 0.09 per share
based upon the closing market price on the date of grant. The aggregate grant date fair value of the awards amounted to $
360,000, which will be recognized as compensation expense over the vesting period. The Company recorded $ 180,000 of
compensation expense during the six months ended May 31, 2014 with respect to these awards. Total unrecognized compensation
expense related to unvested stock awards at May 31, 2014 and November 30, 2013, amounts to $30,000 and $210,000 respectively,
and is expected to be recognized over a weighted average period of 0.08 years.
A summary of the restricted stock award
activity for the six months ended May 31, 2014 and the year ended November 30, 2013 is as follows:
|
|
|
|
|
|
|
|
Weighted Average
|
|
|
|
|
|
|
|
|
|
Weighted
|
|
|
Remaining
|
|
|
|
|
|
|
Number of
|
|
|
Average Grant
|
|
|
Contractual Life
|
|
|
Aggregate
|
|
|
|
Shares
|
|
|
Date Fair Value
|
|
|
(in Years)
|
|
|
Intrinsic Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested - November 30, 2013
|
|
|
5,500,000
|
|
|
$
|
0.07
|
|
|
|
0.6
|
|
|
$
|
-
|
|
Unvested – May 31, 2014
|
|
|
5,500,000
|
|
|
$
|
0.07
|
|
|
|
0.08
|
|
|
$
|
-
|
|
BioPower Operations Corporation and Subsidiaries
Notes to Consolidated Financial Statements
May 31, 2014
Unaudited
Note 7. Commitments and Contingencies
Commitments
Employment Agreements – Officers
and Directors
As of May 31, 2014, the Company had employment
agreements with certain officers and directors (two individuals) containing the following provisions:
Term of contract 5 years, expiring on
December 31, 2015
Salary $ 120,000
Salary deferral All salaries will be
accrued but may be paid from the Company’s available cash flow funds.
Lease Agreement
On June 3, 2013, the Company entered into
a new lease agreement with its current landlord. The lease is for a 24 month period, expiring on May 31, 2015 , and requires monthly
base rental payments of $ 4,000 for the period from June 1, 2013 through May 31, 2014 and $ 4,080 for the period from June 1, 2014
through May 31, 2015 plus adjustments for Common Area Expenses.
Rent expense was $ 20,549 and $22,029 for
the six month period ended May 31, 2014 and May 31, 2013, respectively.
Contingencies
From time to time, the Company may be involved
in legal matters arising in the ordinary course of business. While the Company believes that such matters are currently not material,
there can be no assurance that matters arising in the ordinary course of business for which the Company is, or could be, involved
in litigation, will not have a material adverse effect on its business, financial condition or results of operations.
Note 8. Testing Services Agreement
On July 2, 2013, the Company entered into agreements for
the first stage of a project to develop a castor plantation and milling operation in the Republic of Paraguay with offshore
entities (aka “Ambrosia” and “Developer”) for the testing and development of a project with up to $
10,000,000 in financing upon certification of the castor yield effective. Under the terms of the Testing Services Agreement
(the “TSA”), the Developer will provide the land, pay costs for the testing and pay the Company a monthly project
management fee of $ 45,000 and reimbursement of expenses during the test period for subcontractors on the ground in Paraguay.
The Company will provide project management testing services through the testing phase for up to 12 months until the
successful certification of the yield from growing castor is proven, subject to material and adverse events. Once Ambrosia
approves the project, then under the Castor Master Farm Management Services Agreement, the $10,000,000 to be invested from
Ambrosia will go towards the development and operations of the first stage of the castor plantation and the building of the
mill and its operations. The Company will earn 6 % of the net income for ten years or have an option to become a 20 % owner
of the project. The Company began the initial test phase in Paraguay on March 20, 2013, and subject to the terms of the TSA,
is entitled to project management fees. The Company recorded other consulting revenue, net of expense, of $38,868 and $85,524
during the three month period ended May 31, 2014 and May 31, 2013, respectively, in connection with services provided under
the TSA.
We received notification of termination
of the TSA project as of April 1, 2014 due to material and adverse events related to the necessity for building roads due to extreme
flooding conditions and issues associated with clearing of the land. All receivables and payables related to the testing services
agreement were satisfied in June 2014.
BioPower Operations Corporation and Subsidiaries
Notes to Consolidated Financial Statements
May 31, 2014
Unaudited
Note 9. Subsequent Events
On July 9, 2014
.
a third
party investor advanced $30,000 at 4% interest due in 60 days from the date of the loan. After 60 days it becomes a demand loan.